
Shares of the biotechnology company Equillium, with a market capitalization of $25.7 million, surged over 15% on Tuesday, August 6. The trigger was positive interim results from the trial of its drug for graft-versus-host disease (GvHD), a condition in which a donor’s immune cells attack a recipient’s body, recognizing it…